|Bid||44.90 x 800|
|Ask||46.55 x 900|
|Day's range||44.12 - 47.60|
|52-week range||43.81 - 93.94|
|Beta (5Y monthly)||1.77|
|PE ratio (TTM)||190.76|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||89.00|
Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -35.29% and -78.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...